News
STSA
1.100
0.00%
0.000
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 06/09/2023 11:30
Satsuma migraine therapy accepted for FDA review
Seeking Alpha · 05/18/2023 20:34
Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(b)(2) NDA For STS101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Benzinga · 05/18/2023 20:03
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review
MT Newswires · 05/18/2023 17:25
Satsuma Pharmaceuticals, Inc.: Current report
Press release · 05/18/2023 16:30
JonesTrading Sticks to Its Hold Rating for Satsuma Pharmaceuticals (STSA)
TipRanks · 05/15/2023 12:05
BRIEF-Shin Nippon Biomedical Laboratories Ltd - Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Reuters · 05/07/2023 23:37
BRIEF-Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
Reuters · 05/03/2023 21:20
More
Webull provides a variety of real-time STSA stock news. You can receive the latest news about Satsuma Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About STSA
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.